Focused on cancers with large patient populations and significant unmet need.
Sign up today and learn more about OncoCyte Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About OncoCyte Stock
OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.The company believes that better and earlier detection of cancer through liquid biopsies will: Improve patient outcomes Increase the life expectancy of cancer patients Significantly reduce health care costs Current diagnostic standards fall short by many measures. At present, diagnostic tests for cancer rely on scans and then tissue samples from invasive surgical procedures to determine if a tumor is benign or malignant.
President & CEO
Yankee Analysts - Jun, 27 2018Oncocyte Corp (OCX) Placed Under the Lens
The Herald - Jun, 27 2018OncoCyte Corporation (AMEX:OCX) Has Yielded YoY Sales Growth of
Park City Caller - Jun, 26 2018Is OncoCyte Corporation (AMEX:OCX) Headed For Earnings Growth?
The Ledger Gazette - Jun, 24 2018OncoCyte (OCX) Stock Price Up 37%
The Lincolnian Online - Jun, 19 2018OncoCyte Corp (NYSEAMERICAN:OCX) Sees Significant Decline in Short Interest
GenomeWeb - May, 15 2018OncoCyte Shrinks Q1 Net Loss; Expects Clinical Validation by Year's End
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase